Form 4: Aquestive Therapeutics Executive Peter E. Boyd Reports Stock and Option Transactions

Peter E. Boyd, an executive at Aquestive Therapeutics, reports the acquisition and disposal of common stock and stock options.

Summary

• On March 7, 2025, Peter E. Boyd acquired 80,000 shares of common stock at $0 and disposed of 6,624 shares at $2.65 to cover tax obligations.
• On March 9, 2025, Boyd disposed of 7,681 shares at $2.65 to cover tax obligations.
• Following these transactions, Boyd directly owns 303,323 shares of common stock.
• Boyd also acquired 40,000 non-qualified stock options with an exercise price of $2.65, vesting in three annual installments, and expiring on March 7, 2035.
• Following these transactions, Boyd directly owns 40,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the amounts are relatively small.

Key Dates